Cinclus Pharma Gains EMA Backing on Manufacturing Plan for GERD Drug

Cinclus Pharma Holding AB ( (SE:CINPHA) ) has provided an announcement.

Cinclus Pharma has received positive scientific advice from the European Medicines Agency on the Chemistry, Manufacturing and Controls strategy for its lead drug candidate linaprazan glurate. The regulator confirmed that the company’s planned manufacturing and quality approach aligns with requirements for a future marketing authorization application and clarified the additional data expected.

This endorsement, which follows similar feedback from the U.S. Food and Drug Administration, enhances Cinclus Pharma’s regulatory readiness and supports its plan to advance linaprazan glurate toward commercialization. By maintaining close dialogue with both regulators, the company seeks to de-risk later-stage development in a large gastroesophageal reflux disease market where there is significant unmet need among severe patients.

The most recent analyst rating on (SE:CINPHA) stock is a Buy with a SEK60.00 price target. To see the full list of analyst forecasts on Cinclus Pharma Holding AB stock, see the SE:CINPHA Stock Forecast page.

More about Cinclus Pharma Holding AB

Cinclus Pharma Holding AB is a late-stage clinical pharmaceutical company focused on developing drugs for acid-related diseases and disorders of the upper gastrointestinal tract. Its lead candidate, linaprazan glurate, a prodrug of P-CAB linaprazan originally developed by AstraZeneca, targets gastroesophageal reflux disease and aims to outperform existing proton pump inhibitor therapies based on extensive phase I and II data and an ongoing phase III program.

Average Trading Volume: 44,502

Technical Sentiment Signal: Sell

Current Market Cap: SEK784.6M

See more insights into CINPHA stock on TipRanks’ Stock Analysis page.